Dividends4Life: PDLI Fuses Dividends With Biopharma

PDLI Fuses Dividends With Biopharma

Posted by D4L | Friday, September 05, 2014 | | 0 comments »

It’s not often one hears the word “dividends” and “biopharma” in the same sentence, except maybe to point out that the two never seem to go hand-in-hand. Yet, there are (rare) exceptions to that norm. One of those exceptions is PDL Biopharma (PDLI). Incredibly enough, PDLI currently boasts a dividend yield of 6.1%. Better still, PDL Biopharma is apt to keep paying solid dividends for the foreseeable future. Income investors looking to beef up their portfolio’s diversity may want to mull PDLI. Here’s a closer look at the details.

PDL Biopharma is so unique that there’s not really a category for it within the investment world. The most relevant analogy would be to describe PDLI as a REIT (real estate investment trust) or an MLP (master limited partnership) for the pharmaceutical world. Though the company doesn’t enjoy the tax benefits of being a REIT, nor does it pass along the tax-filing work required of MLP owners, PDL Biopharma was built from the ground up as a machine that pays out the bulk of its income as dividends.

Source: InvestorPlace

Related Articles:
- 12 Dividend Stocks With 50+ Years of Consecutive Increases
- 8 Dividend Stocks With A 15% Yield In 15 Years
- First Quarter 2014: Top And Bottom Performing Dividend Stocks
- Don't Touch These 5 Dividend Stocks!
- 7 Dividend Stocks Headed In The Right Direction

Click here to have future posts delivered to you for free!



Post a Comment

Note: Only a member of this blog may post a comment.


Popular Posts Last 30 Days